Monitoring AML1-ETO mRNA levels by real-time quantitative RT-PCR in t(8;21) acute myeloid leukemia patients after hematopoietic stem cell transplantation.
- Author:
Zhi-Dong WANG
1
;
Ya-Zhen QIN
;
Yan-Rong LIU
;
Lan-Ping XU
;
Dai-Hong LIU
;
Kai-Yan LIU
;
Xiao-Jun HUANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Core Binding Factor Alpha 2 Subunit; genetics; metabolism; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; metabolism; surgery; Male; Middle Aged; Oncogene Proteins, Fusion; genetics; metabolism; RNA, Messenger; genetics; RUNX1 Translocation Partner 1 Protein; Reverse Transcriptase Polymerase Chain Reaction; methods; Young Adult
- From: Chinese Journal of Hematology 2008;29(10):672-675
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the value of real time quantitative RT-PCR (Q-PCR) for monitoring AML1-ETO mRNA levels in AML1-ETO(+) acute myeloid leukemia (AML) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODSQuantification of AML1-ETO(+) mRNA was performed serially on bone marrow samples from 17 patients with AML1-ETO(+) AML after HSCT. Q-PCR used the TagMan probe system. The AML1-ETO mRNA level was normalized by control gene abl. Cytogenetic response was evaluated by fluorescent in situ hybridization (FISH).
RESULTSThe reproducible sensitivity of Q-PCR was 5 copies. Out of 16 patients who achieved sustained complete cytogenetic response (CCyR), one each died of graft-versus-host disease and infection. The median AML1-ETO mRNA levels in the rest of 14 CCyR patients were 0 (0 - 0.740), 0.026 (0 - 2.900), 0.039 (0 - 3.300) at +1, +2, +3 month post allo-HSCT, respectively and in 5 CCyR patients beyond 1 year following allo-HSCT (median follow-up 685 days) was 0.078 (0.003 - 0.120). The AML1-ETO mRNA levels in one relapsed patient were 0, 9.8 and 5.6 at +1, +2 and +3 month post allo-HSCT, respectively and hematological relapse occurred at +110 day, when the AML1-ETO mRNA levels increased dramatically from 5.600 to 390.000.
CONCLUSIONSQ-PCR is a sensitive technique in monitoring AML1-ETO(+) AML patients post allo-HSCT. Persistence of a low level within one year after allo-HSCT does not mean at risk of relapse. It is necessary to dynamic monitoring AML1-ETO mRNA after remission in t(8;21) AML patients.
